Lario Therapeutics Ltd. has divulged voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) blockers reported to be useful for the treatment of neurodegeneration, neurodevelopmental disorders, epilepsy, Parkinson’s disease, endocrine disorders, cerebral vasospasm, pain and epileptic encephalopathy.

Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition following SARS-CoV-2 infection associated with intestinal manifestations. The most common clinical features include fever, abdominal pain, rash, myocardial dysfunction and elevated inflammatory biomarkers.

Deficiencies in the SLC6A1 gene, encoding the γ-aminobutyric acid transporter GAT-1, are associated with infantile encephalopathy with intellectual disability. Like other neurodevelopmental disorders, SLC6A1-related disorders lack effective treatments; therefore, gene therapy using viral vectors has been proposed as a potential therapeutic strategy.

Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose.

Azole derivatives have been used as antifungal drugs in clinical practice for many years. However, limitations such as drug-drug interactions, severe adverse events from prolonged use, and high resistance prevalence highlight the urgent need for new therapeutic options to treat the rising number of invasive fungal infections.